MedTrace Logo

Trem-1 and Ultraviolet Radiation-induced Immune Suppression

NCT05020496 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-06-29

No results posted yet for this study

Summary

The overall goal of this study is to determine novel mechanisms for ultraviolet light (UV)-induced suppression of the immune system in human subjects and to improve understanding of UV-induced skin carcinogenesis.

Conditions

  • Skin Diseases

Interventions

DRUG

Diphenylcyclopropenone (DPCP)

Drug will be applied topically on the skin. It will cause contact hypersensitivity in patients

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Craig Elmets, MD · Univ. of Alabama at Birmingham

  • Tyler Downing, MD · University of Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-21
Primary Completion
2026-06-30
Completion
2026-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05020496 on ClinicalTrials.gov